Valuation: Roche Holding AG

Market Cap 289B 356B 309B 264B 496B 33,975B 504B 3,406B 1,330B 17,007B 1,336B 1,308B 56,733B P/E 2026 *
20.2x
P/E 2027 * 17.9x
Enterprise Value 300B 369B 320B 274B 515B 35,251B 523B 3,534B 1,380B 17,646B 1,387B 1,357B 58,864B EV / Sales 2026 *
4.79x
EV / Sales 2027 * 4.48x
Free-Float
88.78%
Yield 2026 *
2.76%
Yield 2027 * 2.82%
1 day+10.31%
Current month+0.48%
6 months-10.15%
Current year-1.29%
Current year 311.6
Extreme 311.6
377
1 year 249.6
Extreme 249.6
377
3 years 212.3
Extreme 212.3
377
5 years 212.3
Extreme 212.3
404.1
10 years 202.23
Extreme 202.231
404.1
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
+10.30%0.00% - - 356B
-0.92%+1.43%+83.05%+128.86% 1,078B
+0.47%+1.98%+50.26%+50.75% 632B
+0.83%+2.85%+24.49%+64.82% 443B
-1.39%-2.64%+42.98%+35.02% 356B
-1.23%-2.91%+24.09%+34.54% 289B
-1.63%-3.11%-0.52%+3.71% 245B
+0.40%+3.21%+44.42%+59.17% 226B
+1.09%-1.33%-7.23%-51.39% 204B
+1.67%+5.56%+14.98%+72.68% 171B
Average +0.65%+1.43%+30.73%+44.24% 404.85B
Weighted average by Cap. +0.67%+1.30%+45.39%+65.42%

Financials

2026 *2027 *
Net sales 62.64B 77.1B 66.83B 57.12B 107B 7,358B 109B 738B 288B 3,683B 289B 283B 12,287B 65.47B 80.57B 69.84B 59.7B 112B 7,690B 114B 771B 301B 3,849B 302B 296B 12,841B
Net income 14.51B 17.85B 15.47B 13.23B 24.89B 1,704B 25.29B 171B 66.68B 853B 67.02B 65.57B 2,845B 16.33B 20.1B 17.42B 14.89B 28.02B 1,918B 28.47B 192B 75.08B 960B 75.46B 73.83B 3,203B
Net Debt 10.87B 13.37B 11.59B 9.91B 18.64B 1,276B 18.94B 128B 49.95B 639B 50.21B 49.12B 2,131B 4.02B 4.95B 4.29B 3.67B 6.9B 472B 7.01B 47.33B 18.48B 236B 18.57B 18.17B 788B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
26-08-13 CHF 323.90 0.00% 58,974
26-08-12 CHF 323.90 0.00% 81
26-08-11 CHF 323.90 0.00% 495
26-08-10 CHF 323.90 0.00% 152,626
26-08-07 CHF 323.90 0.00% 3,574
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
362.30CHF
Average target price
370.31CHF
Spread / Average Target
+2.21%

Quarterly revenue - Rate of surprise